MecRx awarded $900,000 Biomedical Translation Bridge Award by MTP Connect. MecRx awarded $900,000 Biomedical Translation Bridge Award by MTP Connect.

MecRx Pty Ltd has been announced as one of the eight successful applicants for Round One funding from the Biomedical Translation Bridge Program to develop novel, small molecule therapeutics for the treatment of lung cancer.

The Biomedical Translation Bridge program is an initiative of the Medical Research Future Fund, providing up to $1 million in matching funding to nurture the translation of new therapies, technologies and medical devices through to the proof-of-concept stage. The BTB program is operated by MTPConnect, in partnership with BioCurate (University of Melbourne and Monash University), UniQuest (University of Queensland through its drug discovery initiative QEDDI), the Medical Device Partnering Program (MDPP, led by Flinders University), and the Bridge and BridgeTech programs (Queensland University of Technology); all pre-eminent organisations engaged in the translation and commercialisation of health and medical research.

Further information about MTP Connect and the Biomedical Translation Bridge Program